Liposome-based Adjuvant containing two delivery systems ability to indicate Mucosal Immunoglobulin after parenteral immunization


Abstract imagery

In the world, hospital infections are the third of all causes of the gravity of the disease and vaccines are needed for strong and long-term immune reactions. Parenteral immunization generally does not produce intestinal IgA. However, shortly before the start of the vaccine before the vaccination vaccine before the vaccination of the vaccine, the parasitic vaccine strategy was involved in the intestinal ir. As multiple injections of vaccination are not an attractive strategy for clinical practice, we aimed to develop the formulation of a single vaccine vaccine that was causing parenteral control. Our vaccine formulation contained two liposomal delivery systems. One delivery system, based on a 1,2-sn– Glycerio-3-phosphoclinine is stable with PEG, which aimed at rapidly draining local lymph nodes in order to make preconditions to the vaccine antigen before the mucous immune response. The other delivery system based on the stability of the liposomes of the cholesterol lactic acid CAF01 is optimized for the long-term supply of antigen for the lymph node preceded by migratory antigen preparations. Combined we call adjuvant CAF23. We show that CAF23 is responsible for the reaction of the specific intestinal IgA to the antigen, which results in a promising candidate for vaccines against adigenous diseases.

Support information is free at ACS publications website: DOI: 10.1021 / acsnano.8b05209.

  • Adding CAF01 adjuvant in Resistant Response with Retino Acid in Oil Solution; Stools, intestines and serum in IgA after immunization of CAF16 and CAF23; IgG1, IgG2a, IgG2b and IgG2c Titles CAF01 and CAF23 (PDF)